c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death

Molecular Medicine

Volumn 18, Issue 2, 2012, Pages 167-177

  Bu, Rong ^a   Uddin, Shahab ^a   Ahmed, Maqbool ^a   Hussain, Azhar R ^a   Alsobhi, Saif ^a   Amin, Tarek ^a   Al Nuaim, Abdurahman ^a   Al Dayel, Fouad ^a   Abubaker, Jehad ^a   Bavi, Prashant ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; B RAF KINASE; DEATH RECEPTOR 5; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COHORT ANALYSIS; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; THYROID PAPILLARY CARCINOMA; TISSUE MICROARRAY; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; HUMANS; INDOLES; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-MET; SULFONES; THYROID NEOPLASMS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84859081753     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00238     Document Type: Article

References (44)

1. Nikiforov YE. (2008) Thyroid carcinoma: molecular pathways and therapeutic targets. Mod. Pathol. 21(Suppl 2):S37-43.
2. Piersanti M, Ezzat S, Asa SL. (2003) Controversies in papillary microcarcinoma of the thyroid. Endocr. Pathol. 14:183-91.
3. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP. (1997) Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J. Clin. Endocrinol. Metab. 82:3553-62.
4. Hay ID. (1990) Papillary thyroid carcinoma. Endocrinol. Metab. Clin. North Am. 19:545-76.
5. Siironen P, et al. (2005) Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol. 26:57-64.
6. Gonzatti-Haces M, et al. (1988) Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc. Natl. Acad. Sci. U. S. A. 85:21-5.
7. Bardelli A, Ponzetto C, Comoglio PM. (1994) Identification of functional domains in the hepatocyte growth factor and its receptor by molecular engineering. J. Biotechnol. 37:109-22.
8. Lesko E, Majka M. (2008) The biological role of HGF-MET axis in tumor growth and development of metastasis. Front. Biosci. 13:1271-80.
9. Desiderio MA. (2007) Hepatocyte growth factor in invasive growth of carcinomas. Cell. Mol. Life Sci. 64:1341-54.
10. Tulasne D, Foveau B. (2008) The shadow of death on the MET tyrosine kinase receptor. Cell. Death Differ. 15:427-434.
11. Mineo R, et al. (2004) Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels. Endocrinology. 145:4355-65.
12. Ruco LP, Stoppacciaro A, Ballarini F, Prat M, Scarpino S. (2001) Met protein and hepatocyte growth factor (HGF) in papillary carcinoma of the thyroid: evidence for a pathogenetic role in tumourigenesis. J. Pathol. 194:4-8.
13. Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. (2003) Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin. Cancer Res. 9:68-75.
14. Siraj AK, et al. (2007) Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J. Pathol. 213:190-9.
15. Bauer J, Wekerle H, Lassmann H. (1995) Apoptosis in brain-specific autoimmune disease. Curr. Opin. Immunol. 7:839-43.
16. Ghobrial IM, Witzig TE, Adjei AA. (2005) Targeting apoptosis pathways in cancer therapy. C. A. Cancer J. Clin. 55:178-94.
17. Bavi P, et al. (2006) Prevalence of fragile histidine triad expression in tumors from Saudi Arabia: a tissue microarray analysis. Cancer Epidemiol. Biomarkers Prev. 15:1708-18.
18. Uddin S, et al. (2008) Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J. Clin. Endocrinol. Metab. 93:4088-97.
19. Uddin S, et al. (2006) Role of phosphatidylinositol 33-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood. 108:4178-86.
20. Abubaker J, et al. (2008) Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene. 27:3539-45.
21. Mandal M, et al. (2005) The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br. J. Cancer. 92:1899-905.
22. Hussain AR, et al. (2006) Curcumin induces apoptosis via inhibition of PI3v-kinase/AKT pathway in acute T cell leukemias. Apoptosis. 11:245-54.
23. Uddin S, Hussain A, Al-Hussein K, Platanias LC, Bhatia KG. (2004) Inhibition of phosphatidylinositol 33-kinase induces preferentially killing of PTEN-null T leukemias through AKT pathway. Biochem. Biophys. Res. Commun. 320:932-8.
24. Hussain AR, et al. (2007) Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. Cancer Res. 67:3888-97.
25. Uddin S, Ah-Kang J, Ulaszek J, Mahmud D, Wickrema A. (2004) Differentiation stage-specific activation of p38 mitogen-activated protein kinase isoforms in primary human erythroid cells. Proc. Natl. Acad. Sci. U. S. A. 101:147-52.
26. Uddin S, et al. (2005) Inhibition of phosphatidylinositol 33-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells. Clin. Cancer Res. 11:3102-8.
27. Christensen JG, Burrows J, Salgia R. (2005) c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 225:1-26.
28. Tjin EP, et al. (2006) Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma. Blood. 107:760-8.
29. Bu R, et al. (2011) HGF/c-Met pathway has a prominent role in mediating antiapoptotic signals through AKT in epithelial ovarian carcinoma. Lab. Invest. 91:124-37.
30. Mukohara T, et al. (2005) Inhibition of the met receptor in mesothelioma. Clin. Cancer Res. 11:8122-30.
31. Samovski D, Kalderon B, Yehuda-Shnaidman E, Bar-Tana J. (2010) Gating of the mitochondrial permeability transition pore by long chain fatty acyl analogs in vivo. J. Biol. Chem. 285:6879-90.
32. Chou WC, Dang CV. (2005) Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Curr. Opin. Hematol. 12:1-6.
33. Jung EM, Lim JH, Lee TJ, Park JW, Choi KS, Kwon TK. (2005) Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis. 26:1905-13.
34. Ma PC, Maulik G, Christensen J, Salgia R. (2003) c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 22:309-25.
35. Furge KA, Zhang YW, Vande Woude GF. (2000) Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene. 19:5582-9.
36. Sawada K, et al. (2007) c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 67:1670-9.
37. Koon EC, et al. (2008) Effect of a c-Met-specific, ATP-competitive small-molecule inhibitor SU11274 on human ovarian carcinoma cell growth, motility, and invasion. Int. J. Gynecol. Cancer. 18:976-84.
38. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. (2001) Anti-apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways. Proc. Natl. Acad. Sci. U. S. A. 98:247-52.
39. Chen BK, et al. (1999) Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage. Pathol. Res. Pract. 195:427-33.
40. Ramirez R, et al. (2000) Over-expression of hepatocyte growth factor/scatter factor (HGF/SF) and the HGF/SF receptor (cMET) are associated with a high risk of metastasis and recurrence for children and young adults with papillary thyroid carcinoma. Clin. Endocrinol. 53:635-44.
41. Chattopadhyay C, El-Naggar AK, Williams MD, Clayman GL. (2008) Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma. Head Neck. 30:991-1000.
42. Abubaker J, et al. (2008) Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J. Clin. Endocrinol. Metab. 93:611-8.
43. Kumagai A, et al. (2006) No evidence of ARAF, CRAF and MET mutations in BRAFT1799A negative human papillary thyroid carcinoma. Endocr. J. 53:615-20.
44. Zhang L, Fang B. (2005) Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene. Ther. 12:228-37.